Related Experiment Videos
Gene replacement strategies for cancer
1Department of Thoracic Surgery, University of Texas M.D. Anderson Cancer Center, Houston, USA.
Abstract:
The strategy for the inactivation or replacement of cancer-causing genes is analogous to the classic concept of gene therapy for replacement of defective or nonfunctioning genes. The gene families implicated in carcinogenesis include dominant oncogenes and tumor suppressor genes. Regional administration of viral vectors expressing wildtype p53 and antisense K-ras prevents growth for tumors with the specific genetic lesions in orthotopic tumor models and mediates regression of large established tumors. These studies provide a rationale for a new clinical protocol recently approved by the United States National Institutes of Health (NIH) Recombinant DNA Advisory Committee and the Federal Drug Administration (FDA) to replace a defective p53 gene with intratumor injection of recombinant retrovirus expressing normal p53 and to inactivate mutant K-ras by expression of antisense K-ras mRNA. If these agents are efficacious, their lack of toxicity may provide a sufficiently high therapeutic index such that they could be used as an adjuvant to surgery to treat patients with earlier stages of cancer or as prevention for second primary cancers for individuals with genetic abnormalities in premalignant lesions. Although much research needs to be done, the possibility of specific gene targeting with a high therapeutic index makes this a promising area for investigation.
Insights
Gene therapy offers a promising strategy for cancer treatment by replacing defective genes like p53 and inactivating oncogenes such as K-ras. This approach shows potential for preventing cancer recurrence and treating early-stage disease.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Cancer arises from genetic mutations in oncogenes and tumor suppressor genes.
- Gene therapy offers a novel strategy for targeting these genetic alterations.
Purpose of the Study:
- To evaluate the efficacy of gene therapy for inactivating oncogenes and replacing tumor suppressor genes in cancer treatment.
- To provide a rationale for clinical trials using gene replacement and inactivation strategies.
Main Methods:
- Utilizing viral vectors for regional administration of wildtype p53 and antisense K-ras.
- Employing orthotopic tumor models to assess tumor growth prevention and regression.
- Developing recombinant retroviruses for intratumor injection to deliver therapeutic genes.
Main Results:
- Viral vectors expressing wildtype p53 and antisense K-ras prevented tumor growth in models with specific genetic lesions.
- Established tumors showed regression upon treatment with these gene therapy agents.
- The approach demonstrated a potential for high therapeutic index with low toxicity.
Conclusions:
- Gene therapy targeting specific genetic defects offers a promising approach for cancer treatment.
- This strategy could serve as an adjuvant to surgery or for preventing second primary cancers.
- Further research is needed, but specific gene targeting shows significant potential in oncology.